Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30‐positive aggressive lymphomas

OBJECTIVES: A treatment regimen consisting of bendamustine and brentuximab vedotin (BV) has been described as a highly potent salvage therapy and as an effective induction therapy leading to high response rates before autologous stem cell transplantation (ASCT) in patients with classical Hodgkin lym...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur J Haematol
Autors principals: Wagner, Sandro M., Melchardt, Thomas, Egle, Alexander, Magnes, Teresa, Skrabs, Cathrin, Staber, Philipp, Simonitsch‐Klupp, Ingrid, Panny, Michael, Lehner, Barbara, Greil, Richard, Keil, Felix, Jäger, Ulrich, Sillaber, Christian
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2020
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065019/
https://ncbi.nlm.nih.gov/pubmed/31838747
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13368
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars